Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACNS1123: Response-Based RT for Localized CNS GCT
NCT01602666Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2012
- Primary completion
- Sep 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 2, open-label trial of carboplatin, etoposide and ifosfamide in Central nervous system non-germinomatous germ cell tumors and germinoma, sponsored by Children's Oncology Group. Started Jun 2012; status: completed.
02
Drugs
carboplatinetoposideifosfamide
03
Conditions
Central nervous system non-germinomatous germ cell tumorsgerminoma
Beyond the preview
Go deeper on NCT01602666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602666.